Outcomes4Me

Oncology Clinical Trial Finder

Breast Cancer
Location

Breast Cancer

(50 of 1924)

Sort:

Relevance

NCT04529044

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

This phase II trial investigates how well 177Lu-DOTATATE works in treating patients with breast cancer that is stage IV or has come back (recurrent). 177Lu-DOTATATE may shrink or destroy the tumor or circulating breast cancer stem cells if they show evidence of the SSTR2. 177Lu-DOTATATE is a targeted therapy that uses DOTATATE, linked to a radioactive agent called 177Lu. DOTATATE attaches to tumor cells with SSTR2 and delivers 177Lu to kill them. Giving 177Lu-DOTATATE may help decrease the number and size of tumors and the number of circulating cancer stem cells in patient's blood for the treatment of patients with breast cancer positive for SSTR2.

Not yet recruiting • Phase II • Stage IV • ER positive • Medical Oncology • Post-Menopausal • Interventional

OHSU Knight Cancer Institute

Site Contact

SuEllen Pommier

pommiers@ohsu.edu

503-494-5034

Principal Investigator

SuEllen Pommier

Last Updated: 

11/18/2021


OHSU Knight Cancer Institute

Site Contact

SuEllen Pommier

pommiers@ohsu.edu

503-494-5034

Principal Investigator

SuEllen Pommier

Last Updated: 

05/25/2021

NCT02409316

[18F]FES PET/CT in Endocrine Refractory Breast Cancer

In this study, positron emission tomography (PET/CT) imaging will be used to evaluate estrogen receptor (ER) activity in sites of metastatic disease using the investigational radiotracer [18F]fluoroestradiol (FES).

Active, not recruiting • Phase NA • Stage IV • Surgical • Radiation • Post-Menopausal • Interventional

University of Pennsylvania Hospital

Principal Investigator

David Mankoff, MD. PhD

Last Updated: 

05/25/2021

NCT03863457

[18F] F-GLN by PET/CT in Breast Cancer

Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC). This is an observational study; [18F]F-GLN PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the [18F]F-GLN PET/CT results, treatment decisions are made by the treating physicians based upon clinical criteria. [18F]F-GLN PET/CT imaging sessions will include an injection of [18F]F-GLN. Metabolism data will be collected. Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of [18F]F-GLN in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of [18F]F-GLN will also be evaluated in all subjects.

Recruiting • Phase I • Stage IV • Post-Menopausal • Non-interventional

University of Pennsylvania

Site Contact

Erin Schubert

erin.schubert@pennmedicine.upenn.edu

215-573-6569

Principal Investigator

Austin Pantel, MD

Last Updated: 

05/25/2021

NCT02608216

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer [18F]fluorothymidine (FLT).

Active, not recruiting • Phase I • Stage IV • Surgical • Post-Menopausal • Interventional

University of Pennsylvania Hospital

Principal Investigator

David Mankoff, MD, PhD

Last Updated: 

05/25/2021

NCT01621906

18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain

The purpose of this study is to compare two different imaging methods to examine the response of brain metastases to WBRT. These two imaging methods will take pictures of the brain using : 1) a positron emission tomography (PET) scanner and 2) Magnetic Resonance Imaging (MRI) scanner. A PET scanner resembles a CT or MR scanner.PET scans use radioactive substances also called as radioactive markers to "see" cancer cells. We plan to use [18F]FLT as a radioactive marker. FLT is used to image tumor growth. FLT PET scan is a new clinical procedure. It is in the testing stage of development unlike FDG-PET which is used more commonly used. Therefore, this is considered a "research" study. This will help us evaluate whether this scan will be safe and better used in the future to evaluate tumors. The amount of radiation to the body is small. The radiation from the radiotracer drug will be gone from the body in a few hours. There is no radiation risk from the MRI scans. Additionally, we also plan to use MRI imaging of the brain. We expect that [18F]FLT PET is better when compared to MRI and will give us more information about the brain metastases after WBRT.

Completed • Phase NA • Stage IV • Surgical • Radiation • Post-Menopausal • Brain Metastases present • Interventional

Memorial Sloan Kettering Cancer Center @ Suffolk

Principal Investigator

Andrew Seidman, MD

Last Updated: 

05/25/2021


Memorial Sloan Kettering at Mercy Medical Center

Principal Investigator

Andrew Seidman, MD

Last Updated: 

05/25/2021


Memorial Sloan Kettering Westchester

Principal Investigator

Andrew Seidman, MD

Last Updated: 

05/25/2021


Memorial Sloan Kettering Cancer Center

Principal Investigator

Andrew Seidman, MD

Last Updated: 

05/25/2021


Memorial Sloan Kettering Monmouth

Principal Investigator

Andrew Seidman, MD

Last Updated: 

05/25/2021

NCT04727632

[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial

This protocol is a companion imaging study that will add FES-PET/CT imaging to the FORESEE trial at HCI. This study will establish the feasibility of using FES-PET/CT imaging to guide therapeutic decision making for functional precision oncology trials. The unique ability of FES-PET/CT to show absence of functional estrogen receptors throughout the entire body may improve confidence among research oncologists that an ER+ metastatic breast cancer patient is truly refractory to hormonal therapies which is a critical determination in the study design of the FORESEE trial.

Recruiting • Phase NA • Stage IV • ER positive • Post-Menopausal • Interventional

Huntsman Cancer Institute at University of Utah

Site Contact

Matt Covington, MD

matt.covington@hci.utah.edu

801-585-5942

Principal Investigator

Matthew Covington, MD

Last Updated: 

05/25/2021

NCT04252859

[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma

FES PET/CT imaging for invasive lobular cancer

Recruiting • Phase II • Stage IV • Surgical • Post-Menopausal • Interventional

Huntsman Cancer Institute

Site Contact

Regan Butterfield Schuchart

Regan.Butterfield@hci.utah.edu

Principal Investigator

Matthew Covington, MD

Last Updated: 

05/25/2021

NCT04752267

18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases

This early phase I trial tests the use of a radioactive tracer (a drug that is visible during an imaging test) known as 18F-FMAU, for imaging with positron emission tomography/computed tomography (PET/CT) in patients with brain cancer or cancer that has spread to the brain (brain metastases). A PET/CT scan is an imaging test that uses a small amount of radioactive tracer (given through the vein) to take detailed pictures of areas inside the body where the tracer is taken up. 18F-FMAU may also help find the cancer and how far the disease has spread. Magnetic resonance imaging (MRI) is a type of imaging test used to diagnose brain tumors. 18F-FMAU PET/CT in addition to MRI may make the finding and diagnosing of brain tumor easier.

Active, not recruiting • Phase O • Stage IV • Post-Menopausal • Brain Metastases present • Interventional

USC / Norris Comprehensive Cancer Center

Principal Investigator

Hossein Jadvar, MD

Last Updated: 

05/25/2021

NCT02284919

[18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer

In this study, positron emission tomography (PET/CT) imaging will be used to evaluate sigma-2 (σ2) receptor activity in sites of primary breast cancer using the investigational radiotracer [18F]ISO-1.

Active, not recruiting • Phase I • Stages 0, I, II, III, IV • Post-Menopausal • Interventional

University of Pennsylvania Hospital

Principal Investigator

Elizabeth McDonald, MD, PhD

Last Updated: 

05/25/2021

NCT02624700

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

This phase 2 clinical trial will evaluate the efficacy of the combination of pemetrexed and sorafenib in patients with recurrent or metastatic Triple Negative Breast Cancer (TNBC). Candidate pharmacodynamic and predictive biomarkers will also be evaluated.

Terminated • Phase II • Stages III, IV • ER negative • PR negative • HER2 negative • Medical Oncology • Post-Menopausal • Interventional

Virginia Commonwealth University/Massey Cancer Center

Principal Investigator

Andrew S Poklepovic, MD

Last Updated: 

05/25/2021

NCT04136912

3-D Super Resolution Ultrasound Microvascular Imaging

This is a 3-arm single center study of 45 patients. These cohorts will include 15 breast patients scheduled to undergo a biopsy, and 15 thyroid patients scheduled to undergo fine needle aspiration, biopsy, or thyroidectomy that consent to undergo an acoustic angiography in conjunction with b-mode ultrasound prior to their scheduled biopsy. Prior to imaging clinical patients, the third arm will include 15 healthy volunteers that will be imaged to optimize imaging parameters.

Recruiting • Phase NA • Stages 0, I, II, III, IV • ER negative • Post-Menopausal • Interventional

Univeristy of North Carolina Chapel Hill

Site Contact

Carly Sronce

carly_sronce@med.unc.edu

919-966-3262

Principal Investigator

Yueh Lee, MD, PhD

Last Updated: 

05/25/2021

NCT04692818

3D Ultrasound Breast Imaging

The purpose of this research is to study the efficacy of a new ultrasound imaging method for diagnosis of breast mass.

Recruiting • Phase NA • Stages 0, I, II, III, IV • Post-Menopausal • Interventional

Mayo Clinic in Rochester

Site Contact

Bobbie Ott

ott.bobbie@mayo.edu

507-293-0922

Principal Investigator

Shigao Chen

Last Updated: 

05/25/2021

NCT05704283

3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer

This early phase I studies how well a new 3D ultrasound (3D-US) imaging technology works in evaluating axillary lymph nodes in patients with breast cancer. Ultrasound uses high-frequency sound waves to generate images of the body.

Recruiting • Phase O • Stages 0, I, II, III, IV • Post-Menopausal • Interventional

Mayo Clinic in Rochester

Site Contact

Clinical Trials Referral Office

mayocliniccancerstudies@mayo.edu

855-776-0015

Principal Investigator

Shigao D Chen

Last Updated: 

01/31/2023

NCT04925817

3D Ultrasound Microvessel Imaging for Breast Masses

This early phase I trial studies how well 3D ultrasound microvessel imaging works for the diagnosis of breast mass. The 3D ultrasound microvessel imaging technology demonstrates significantly increased vessel detection sensitivity over conventional doppler methods without the need of using contrast agents. This study may improve cancer diagnosis and reduce unnecessary biopsy on benign tumors.

Recruiting • Phase O • Stages 0, I, II, III, IV • Post-Menopausal • Interventional

Mayo Clinic in Rochester

Site Contact

Clinical Trial Referral Office

mayocliniccancerstudies@mayo.edu

855-776-0015

Principal Investigator

Shigao D Chen

Last Updated: 

06/15/2021

NCT03364348

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

This trial studies the best dose and side effects of utomilumab (4-1BB agonist monoclonal antibody PF-05082566) with trastuzumab emtansine or trastuzumab in treating patients with HER2-positive breast cancer that has spread to other places in the body. Monoclonal antibodies, such as utomilumab, trastuzumab emtansine, and trastuzumab may interfere with the ability of tumor cells to grow and spread.

Completed • Phase I • Stages III, IV • Medical Oncology • Post-Menopausal • Interventional

Stanford University, School of Medicine

Principal Investigator

George Sledge, MD

Last Updated: 

05/25/2021

NCT03542695

64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy

This early phase I pilot trial studies how well 64Cu-DOTA-alendronate positron emission tomography (PET) imaging work in localizing and characterizing breast calcifications (small calcium deposits) in participants before undergoing mastectomy. Diagnostic procedures, such 64Cu-DOTA-alendronate PET, may detect calcification and help doctors predict cancer associated calcification within breast tissue.

Recruiting • Phase O • Stages 0, I, II, III, IV • Post-Menopausal • Interventional

City of Hope Medical Center

Site Contact

Veronica C. Jones, MD

vjones@coh.org

626-471-7100

Principal Investigator

Veronica Jones, MD

Last Updated: 

05/25/2021

NCT03831711

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.

Suspended • Phase I • Stages I, II, III • Post-Menopausal • Interventional

Stanford Cancer Institute Palo Alto

Principal Investigator

Andrei Iagaru

Last Updated: 

05/25/2021

NCT03678883

9-ING-41 in Patients With Advanced Cancers

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

Recruiting • Phase II • Stages III, IV • Post-Menopausal • Interventional

INCLIVA University of Valencia

Site Contact

Andrés Cervantes, MD

andres.cervantes@uv.es

Last Updated: 

05/25/2021


Hospital Clinico U San Carlos (HSC)

Site Contact

Javier Sastre Valera, MD

Last Updated: 

12/08/2022


START Madrid-HM CIOCC Hospital Universitario

Site Contact

Emiliano Calvo, MD

emiliano.calvo@startmadrid.com

Last Updated: 

05/25/2021


Institut Catala d'Oncologia

Site Contact

Laura Layos Romero

Last Updated: 

12/08/2022


Netherlands Cancer Institute

Site Contact

Andrew P Mazar, PhD

amazar@actuatetherapeutics.com

(858) 922-6618

Last Updated: 

11/18/2021

NCT03962647

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

This is a neoadjuvant study to determine the feasibility and tolerability of 2 weeks of a very low carbohydrate ketogenic diet in combination with letrozole for patients with early stage operable ER+disease.

Recruiting • Phase I • Stages I, II, III • ER positive • Medical Oncology • Post-Menopausal • Brain Metastases absent • Interventional

Vanderbilt-Ingram Cancer Center

Site Contact

Vanderbilt-Ingram Service Information Program

cip@vumc.org

800-811-8480

Principal Investigator

Brent Rexer, MD, PhD

Last Updated: 

05/25/2021

NCT03927768

Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP)

The purpose of this study is to use a magnetic resonance imaging (MRI) sequence called golden-angle radial compressed sensing and parallel imaging (GRASP) as a noninvasive and fast way to measure the wash-in contrast (dye) in the breast. MRI uses a strong magnetic field and radio waves to create images of structures in the body. The goal is to determine if benign and malignant breast lesions have different patterns of contrast wash in. This study will ask woman planning to undergo a clinical breast MRI with contrast (dye) as part of their standard care.

Active, not recruiting • Phase NA • Stages 0, I, II, III, IV • Post-Menopausal • Non-interventional

NYU Langone Health

Principal Investigator

Laura Heacock, MD

Last Updated: 

05/25/2021

NCT03664778

Abbreviated Breast MRI After Cancer Treatment

500 patients will be prospectively recruited to undergo a fast breast MRI examination. The women will be recruited for the study will meet the following criteria: 1. status post primary breast cancer treated with breast conservation therapy 3 years prior to recruitment 2. negative DBT examination six months prior to recruitment 3. all breast densities 4. clinically asymptomatic - no palpable masses, focalthickening, or clinically significant discharge We will identify these patients EPIC database utilizing the date of their last mammogram. The patients will be sent a letter explaining the study and the opportunity to enroll in the study. Interested patients may contact our research coordinators by the phone number provided in the letter. The study recruitment information will also be shared with referring physicians. Physicians may also directly refer patients to the study.

Active, not recruiting • Phase NA • Stage 0 • ER negative • Post-Menopausal • Brain Metastases absent • Non-interventional

UPenn

Principal Investigator

Susan Weinstein, MD

Last Updated: 

05/25/2021

NCT04341129

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic accuracy comparable to that of the conventional full MRI protocol. There are also promising results of ultrafast DCE-MRI studies with shorter breast MRI protocols that provide not only morphologic but also valuable kinetic information about a lesion. The shorter imaging times achieved with the abbreviated and the ultrafast DCE-MRI protocols have the potential to increase efficiency and lower cost by decreasing time in the MRI suite, which in turn may make breast MRI accessible for population-based mass screening. The focus of the proposed research is the investigation of an abbreviated MRI protocol with ultrafast imaging using Dotarem® (Gadoterate Meglumine).

Recruiting • Phase NA • Stages 0, I, II, III, IV • Post-Menopausal • Interventional

University of Chicago Medicine

Site Contact

Brenda Gonzales

BGonzales@radiology.bsd.uchicago.edu

773-702-1089

Principal Investigator

Hiroyuki Abe, MD

Last Updated: 

05/25/2021

NCT04854304

Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts

500 patients will be prospectively recruited to undergo a fast breast MRI examination. The women will be recruited for the study will meet the following criteria: 1. African American 2. negative DBT examination 11 months prior to recruitment 3. Heterogeneously and Extremely breast densities 4. clinically asymptomatic- no palpable masses, focal thickening or clinically significant discharge. Investigators will identify these patients EPIC database utilizing the date of their last mammogram. Interested patients may contact our research coordinators by the phone number provided in the recruitment materials. The study recruitment information will also be shared with referring physicians. Physicians may also directly refer patients to the study.

Recruiting • Phase NA • Stages 0, I, II, III, IV • ER negative • PR negative • HER2 negative • Surgical • Medical Oncology • Post-Menopausal • Interventional

UPENN

Site Contact

Jessica Nunez

Jessica.Nunez@pennmedicine.upenn.edu

215-746-6788

Principal Investigator

Emily F Conant, MD

Last Updated: 

12/06/2021

NCT04305834

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.

Recruiting • Phase II • Stage IV • ER positive • PR positive • HER2 negative • Post-Menopausal • Brain Metastases present • Interventional

City of Hope Medical Center

Site Contact

Mina Sedrak

msedrak@coh.org

626-256-4673

Principal Investigator

Mina Sedrak

Last Updated: 

05/25/2021

NCT04481113

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

This phase I trial tests the side effects and best dose of abemaciclib and niraparib in treating patients with breast cancer that is positive for estrogen or progesterone receptors (hormone receptor positive [HR+]) and HER2 negative. Abemaciclib may stop the growth of tumor cells by blocking certain proteins called cyclin-dependent kinases, which are needed for cell growth. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as niraparib, can keep PARP from working so tumor cells can't repair themselves and grow. Giving abemaciclib and niraparib together before surgery may make the tumor smaller.

Active, not recruiting • Phase I • Stages I, II, III • ER positive • PR positive • HER2 negative • Post-Menopausal • Interventional

OHSU Knight Cancer Institute

Principal Investigator

Alexandra Zimmer, M.D.

Last Updated: 

11/18/2021


OHSU Knight Cancer Institute

Principal Investigator

Alexandra Zimmer, M.D.

Last Updated: 

05/25/2021

NCT03130439

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

This research study is studying a drug called Abemaciclib as a possible treatment for have metastatic triple-negative type of breast cancer.

Terminated • Phase II • Stages III, IV • ER negative • PR negative • HER2 negative • Post-Menopausal • Interventional

Dana-Farber Cancer Institute

Principal Investigator

Sara Tolaney, MD, MPH

Last Updated: 

11/18/2021


Dana-Farber Cancer Institute

Principal Investigator

Sara Tolaney, MD, MPH

Last Updated: 

05/25/2021

NCT05095207

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Recruiting • Phases I, II • Stages III, IV • HER2 negative • Post-Menopausal • Interventional

Dubin breast Center

Site Contact

Atul G Joshi, MS

gargiatul.joshi@mssm.edu

212-824-7320

Principal Investigator

Amy Tiersten, MD

Last Updated: 

10/28/2021


Mount Sinai Beth Israel

Site Contact

Gargi A Joshi, MS

gargiatul.joshi@mssm.edu

212-824-2333

Principal Investigator

Amy Tiersten, MD

Last Updated: 

10/28/2021


Mount Sinai Beth Israel

Site Contact

Gargi A Joshi, MS

gargiatul.joshi@mssm.edu

212-824-2333

Principal Investigator

Amy Tiersten, MD

Last Updated: 

11/18/2021


Mount Sinai - West

Site Contact

Gargi A Joshi, MS

gargiatul.joshi@mssm.edu

212-824-2333

Principal Investigator

Amy Tiersten, MD

Last Updated: 

10/28/2021

NCT03979508

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

This phase II trial studies how well abemaciclib works in treating patients with triple negative breast cancer that can be removed by surgery (resectable) and does not respond to treatment with chemotherapy alone, or in combination with pembrolizumab. Abemaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Recruiting • Phase II • Stages 0, I, II, III • ER negative • PR negative • HER2 negative • Post-Menopausal • Brain Metastases absent • Interventional

Mayo Clinic in Florida

Site Contact

Clinical Trials Referral Office

maycliniccancerstudies@mayo.edu

855-776-0015

Principal Investigator

Matthew P Goetz

Last Updated: 

05/25/2021


Mayo Clinic Florida

Principal Investigator

Matthew P Goetz

Last Updated: 

05/25/2021


Mayo Clinic

Principal Investigator

Matthew P Goetz

Last Updated: 

05/25/2021


Mayo Clinic in Rochester

Site Contact

Clinical Trials Referral Office

mayocliniccancerstudies@mayo.edu

855-776-0015

Principal Investigator

Matthew P Goetz

Last Updated: 

05/25/2021


Mayo Clinic in Arizona

Site Contact

Clinical Trials Referral Office

mayocliniccancerstudies@mayo.edu

855-776-0015

Principal Investigator

Matthew P Goetz

Last Updated: 

05/25/2021

NCT05169567

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.

Recruiting • Phase III • Stages III, IV • HER2 negative • Post-Menopausal • Brain Metastases absent • Interventional

H.R.U Málaga - Hospital Materno-infantil

Site Contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

ClinicalTrials.gov@lilly.com

1-317-615-4559

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Last Updated: 

12/28/2021


Hospital Clínico Universitario Virgen de la Arrixaca

Site Contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

ClinicalTrials.gov@lilly.com

1-317-615-4559

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Last Updated: 

12/28/2021


Hospital Infanta Cristina

Site Contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

ClinicalTrials.gov@lilly.com

1-317-615-4559

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Last Updated: 

05/25/2022


Hospital Universitario Doctor Peset

Site Contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

ClinicalTrials.gov@lilly.com

1-317-615-4559

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Last Updated: 

12/28/2021


Hospital Universitari Son Espases

Site Contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

ClinicalTrials.gov@lilly.com

1-317-615-4559

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Last Updated: 

03/08/2022

NCT04523857

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

This is a Phase II randomized, controlled, open label breast cancer clinical trial. 66 patients will be enrolled. The drugs being studied are hydroxychloroquine (Plaquenil) and abemaciclib (also Verzenio). This research study is testing whether using these drugs to target the disseminated tumor cells in bone marrow can reduce their number or eliminate them. Both hydroxychloroquine and abemaciclib are pills that will be taken twice daily. Both are approved by the FDA

Recruiting • Phase II • Stages I, II, III • ER positive • PR positive • HER2 negative • Post-Menopausal • Interventional

Abramson Cancer Center of the University of Pennsylvania

Site Contact

Lauren Bayne, PhD

lajesse@pennmediicne.upenn.edu

215-349-5398

Principal Investigator

Amy Clark, MD

Last Updated: 

05/25/2021

NCT05086692

A Beta-only IL-2 ImmunoTherapY (ABILITY) Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

Recruiting • Phases I, II • Stages III, IV • ER negative • PR negative • HER2 negative • Post-Menopausal • Interventional

Boca Raton Regional Hospital

Site Contact

Nina Merchant

nmerchant@medicenna.com

604-340-3081

Principal Investigator

Nina Merchant

Last Updated: 

04/14/2022


Princess Margaret Cancer Center

Site Contact

Nina Merchant

nmerchant@medicenna.com

604-340-3081

Principal Investigator

Nina Merchant

Last Updated: 

04/14/2022


Orlando Health Cancer Institute

Site Contact

Nina Merchant

nmerchant@medicenna.com

604-340-3081

Principal Investigator

Nina Merchant

Last Updated: 

04/14/2022


Gabrail Cancer Center Research

Site Contact

Nina Merchant

nmerchant@medicenna.com

604-340-3081

Principal Investigator

Nina Merchant

Last Updated: 

02/18/2022


Emory - Winship Cancer Institute

Site Contact

Nina Merchant

nmerchant@medicenna.com

604-340-3081

Principal Investigator

Nina Merchant

Last Updated: 

08/18/2022

NCT04498520

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

This phase I trial investigates the side effects and best dose of abexinostat and palbociclib when given together with fulvestrant in treating patients with breast or gynecologic cancer. Abexinostat may prevent tumor cells from growing and multiplying and may kill tumor cells. Palbociclib may prevent or slow the growth of tumor cells when used with other anti-hormonal therapy. Estrogen can cause the growth of breast and gynecologic tumor cells. Fulvestrant may help fight breast or gynecologic cancer by blocking the use of estrogen by the tumor cells. Giving abexinostat, palbociclib, and fulvestrant may work better in treating patients with breast or gynecologic cancer.

Withdrawn • Phase I • Stages III, IV • ER positive • PR positive • HER2 negative • Medical Oncology • Post-Menopausal • Interventional

Moffitt Cancer Center

Site Contact

Ricardo L. Costa, MD, MSc

813-745-6100

Principal Investigator

Pamela N Munster, MD

Last Updated: 

05/25/2021


University of California, San Francisco

Site Contact

Denisha Otis

Denisha.Otis@ucsf.edu

415-514-6638

Principal Investigator

Pamela N Munster, MD

Last Updated: 

05/25/2021

NCT03300843

Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

Background: Exomes are the parts of deoxyribonucleic acid (DNA) that make proteins. Researchers are finding a way to read the letters in the exome. Incorrect letters are called mutations. Tumors contain specific mutations. Researchers can find these mutations in tumors to make treatments. Researchers want to use pieces of participants tumors to find the tumor-specific mutations. They also will take participants white blood cells to make a vaccine that they hope will shrink the tumors. Objectives: To see if dendritic vaccine tumor-fighting cells are safe and can cause certain cancer tumors to shrink. Eligibility: Adults ages 18-70 who have metastatic melanoma or metastatic epithelial cancer Design: The first part of this study was done under protocol 03-C-0277. In that study, white blood cells and pieces of participants' tumors were taken to make a vaccine. In this study, participants will get a vaccine every 2 weeks for 8 weeks. It will be given both in a vein and under the skin. At each visit, participants will have a physical exam and have blood taken. They will talk about any side effects they have. After treatment ends, participants will have many follow-up visits for …

Terminated • Phase II • Stage IV • Medical Oncology • Post-Menopausal • Brain Metastases present • Interventional

National Institutes of Health Clinical Center

Principal Investigator

Steven A Rosenberg, M.D.

Last Updated: 

05/25/2021

NCT02788981

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

This is a randomized, placebo-controlled, double-blind, phase II trial of nab-paclitaxel with or without mifepristone for advanced, glucocorticoid receptor-positive, triple-negative breast cancer. A total of 64 patients will receive nab-paclitaxel. Patients will be randomly assigned to either receive placebo or to receive mifepristone daily on the day prior to and day of each dose of nab-paclitaxel. Patients will be enrolled over 12 months and followed for 12 months following completion of study. To expand and follow up on the investigators understanding of a potential pharmacokinetic (PK) interaction between nab-paclitaxel and mifepristone, investigators will perform PK studies in the first 20 patients enrolled at pre-specified "PK sites".

Active, not recruiting • Phase II • Stages III, IV • ER negative • PR negative • HER2 negative • Post-Menopausal • Interventional

Fox Chase Cancer Center

Principal Investigator

Rita Nanda, M.D.

Last Updated: 

05/25/2021


University of Alabama - Birmingham

Principal Investigator

Rita Nanda, M.D.

Last Updated: 

05/25/2021


University of Chicago

Principal Investigator

Rita Nanda, M.D.

Last Updated: 

05/25/2021


Northshore University HealthSystem

Principal Investigator

Rita Nanda, M.D.

Last Updated: 

05/25/2021


Froedtert and the Medical College of Wisconsin

Principal Investigator

Rita Nanda, M.D.

Last Updated: 

05/25/2021

NCT02823262

A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older

The purpose of this research study is to evaluate a decision aid to help women aged 70 and older decide on treatment for their breast cancer.

Completed • Phase NA • Stages 0, I, II, III • ER positive • HER2 negative • Post-Menopausal • Brain Metastases absent • Interventional

Beth Israel Deaconess Medical Center

Principal Investigator

Mara Schonberg, MD MPH

Last Updated: 

05/25/2021


Beth Israel Deaconess Medical Center

Principal Investigator

Mara Schonberg, MD MPH

Last Updated: 

11/18/2021


Dana Farber Cancer Institute

Principal Investigator

Mara Schonberg, MD MPH

Last Updated: 

11/18/2021


Dana Farber Cancer Institute

Principal Investigator

Mara Schonberg, MD MPH

Last Updated: 

05/25/2021

NCT03544268

Academic-Industrial Partnership for Translation of Acoustic Angiography

Purpose: The primary objective of this single arm study is to compare the sensitivity and specificity of acoustic angiography with traditional b-mode ultrasound in the distinction of malignant versus benign breast lesions. Secondary objectives include a comparison of area under the curve (AUC) for acoustic angiography versus b-mode ultrasound, and comparison of radiologist preference for the two imaging techniques for each of 3 lesion characteristics. Participants: Sixty patients who are to have a clinical surgical breast biopsy based on results from pre-study standard of care (SOC) imaging will be recruited from the UNC Breast Clinic for participation in the study. Procedures (methods): This is a one arm single center study of patients with suspicious breast lesions (BIRADS 4 or 5) from the UNC Breast Clinic that consent to undergo an acoustic angiography in conjunction with b-mode ultrasound prior to their scheduled biopsy.

Recruiting • Phase IV • Stages 0, I, II, III, IV • ER negative • Surgical • Medical Oncology • Post-Menopausal • Interventional

UNC Hospitals

Site Contact

Desma Jones, CCRC

desma_jones@med.unc.edu

Principal Investigator

Lee, Yueh-Lun

Last Updated: 

05/25/2021

NCT02526498

Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery

This phase II trial studies how well accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy works in treating patients with breast cancer that has not spread beyond the breast or the axillary lymph nodes (early-stage) after surgery. Radiation therapy uses a type of energy to kill cancer cells and shrink tumors. Brachytherapy is a type of internal radiation therapy that provides radiation inside the breast to any remaining tumor cells next to the space where the tumor was removed, and is given over a shorter amount of time than standard radiation therapy. Giving accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy may reduce the overall time that radiation is delivered to the tumor cells.

Completed • Phase II • Stages 0, I, II • ER positive • PR positive • Post-Menopausal • Brain Metastases absent • Interventional

Montefiore Medical Center

Principal Investigator

Bruce Haffty, MD

Last Updated: 

08/17/2022


21st Centry Oncolgy

Principal Investigator

Bruce Haffty, MD

Last Updated: 

08/17/2022


Rutgers Cancer Institute of New Jersey

Principal Investigator

Bruce Haffty, MD

Last Updated: 

11/18/2021


Rutgers Cancer Institute of New Jersey

Principal Investigator

Bruce Haffty, MD

Last Updated: 

05/25/2021


RWJBarnabas Health - Robert Wood Johnson University Hospital

Principal Investigator

Bruce Haffty, MD

Last Updated: 

08/17/2022

NCT03775213

Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)

The purpose of this research study is to evaluate a decision support tool for patients diagnosed with ductal carcinoma in situ (DCIS).

Completed • Phase NA • Stage 0 • Post-Menopausal • Brain Metastases absent • Interventional

Duke Mammography Clinic

Principal Investigator

Marc D Ryser, PhD

Last Updated: 

05/25/2021

NCT02019303

Accuracy of FNA Versus CNB of Abnormal Axillary Lymph Nodes in Setting of Invasive Breast Cancer

To compare accuracy of ultrasound guided fine needle aspiration (FNA) to core needle biopsy (CNB) of ultrasound detected abnormal axillary lymph nodes in patients with newly diagnosed invasive breast cancer or suspected invasive breast cancer. Hypothesis: FNA and CNB have equivalent diagnostic accuracies In order to prove our hypothesis, we will perform FNA and CNB on the same lymph node in each consented patient. The two samples will be evaluated separately by different pathologists blinded to the material in the other sample. The results of the biopsies will be compared to the gold standard (lymph node excision).

Completed • Phase NA • Stages 0, I, II, III, IV • Post-Menopausal • Interventional

Huntsman Cancer Hospital

Last Updated: 

11/18/2021


Huntsman Cancer Hospital

Last Updated: 

05/25/2021

NCT05001347

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.

Active, not recruiting • Phase II • Stages III, IV • ER negative • PR negative • HER2 negative • Post-Menopausal • Interventional

NCT00887536

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this study.

Completed • Phase III • Stages I, II, III • HER2 negative • Medical Oncology • Post-Menopausal • Brain Metastases absent • Interventional

University College Hospital

Principal Investigator

Norman Wolmark, MD

Last Updated: 

06/16/2021


Bon Secours Hospital

Principal Investigator

Norman Wolmark, MD

Last Updated: 

06/16/2021


Waterford Regional Hospital

Principal Investigator

Norman Wolmark, MD

Last Updated: 

11/18/2021


Waterford Regional Hospital

Principal Investigator

Norman Wolmark, MD

Last Updated: 

06/16/2021


St. Vincent's University Hospital

Principal Investigator

Norman Wolmark, MD

Last Updated: 

06/16/2021

NCT04711252

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer. INFORMATION FOR TRIAL PARTICIPANTS In this trial, the researchers will look at how well camizestrant with palbociclib works, compared with anastrozole with palbociclib, in participants with breast cancer that has either spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of standard endocrine treatment. Participants in this trial will have breast cancer that has ER proteins but does not have overexpression of HER2 protein.

Recruiting • Phase III • Stage IV • ER positive • PR positive • HER2 negative • Post-Menopausal • Interventional

Research Site

Site Contact

AstraZeneca Clinical Study Information Center

information.center@astrazeneca.com

1-877-240-9479

Last Updated: 

11/18/2021


Research Site

Site Contact

AstraZeneca Clinical Study Information Center

information.center@astrazeneca.com

1-877-240-9479

Last Updated: 

11/18/2021


Research Site

Site Contact

AstraZeneca Clinical Study Information Center

information.center@astrazeneca.com

1-877-240-9479

Last Updated: 

11/18/2021


Research Site

Site Contact

AstraZeneca Clinical Study Information Center

information.center@astrazeneca.com

1-877-240-9479

Last Updated: 

05/31/2023


Research Site

Site Contact

AstraZeneca Clinical Study Information Center

information.center@astrazeneca.com

1-877-240-9479

Last Updated: 

11/18/2021

NCT01792726

A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.

TARGIT-Boost is an international randomised clinical trial designed to test the hypothesis that the tumour bed boost delivered as a single dose of targeted intraoperative radiotherapy (TARGIT-B) is superior to the conventional course of external beam radiotherapy boost (EBRT-Boost), especially in women with high risk of local recurrence. It is a pragmatic trial in which each participating centre can use the local predefined inclusion/exclusion criteria for entry into the trial. Only centres with access to the Intrabeam® (Carl Zeiss) are eligible to enter patients into the trial. Eligible patients are those with a higher risk of local recurrence after breast conserving surgery. After giving consent patients are randomised to either TARGIT Boost or EBRT Boost. All patients will receive whole breast EBRT. They may receive any other adjuvant treatments as deemed necessary. The protocol recommends that patients be followed at six monthly intervals for three years and then annually. The primary endpoint is ipsilateral breast recurrence rate. Secondary endpoints are relapse-free survival, site of recurrence, overall survival (breast-cancer specific and non-breast cancer deaths) patient…

Recruiting • Phase NA • Stages I, II, III • ER negative • PR negative • Radiation • Post-Menopausal • Interventional

Hospital Universitario Dr Negrín

Site Contact

Pedro C Lara, MD

Principal Investigator

Jayant S Vaidya, MBBS FRCS

Last Updated: 

06/16/2021


Netcare Milpark Hospital

Site Contact

Kyara Bergstrom

Principal Investigator

Jayant S Vaidya, MBBS FRCS

Last Updated: 

06/16/2021


Institut Català d'Oncologia

Site Contact

Montse Ventura

montseventura@iconcologia.net

Principal Investigator

Jayant S Vaidya, MBBS FRCS

Last Updated: 

06/16/2021


Institut Universitaire du Cancer de Toulouse - Oncopole

Site Contact

Francoise Izar, MD

Principal Investigator

Jayant S Vaidya, MBBS FRCS

Last Updated: 

06/16/2021


Hôpital Nord

Site Contact

Didier Cowen, MD

Principal Investigator

Jayant S Vaidya, MBBS FRCS

Last Updated: 

06/16/2021

NCT04594473

A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors

The objective of this study is to demonstrate the feasibility and acceptability of the algorithm utilized within a cancer rehab program, named Comprehensive Oncology Rehabilitation and Exercise (CORE) program, among newly diagnosed stage I-III breast cancer survivors, providers, and clinic staff. Additionally, this study aims to generate preliminary estimates on the extent to which CORE, compared with standard of care (SOC), elicits engagement in exercise and impacts changes in physical function and quality of life within this population.

Recruiting • Phase NA • Stages 0, I, II, III, IV • Post-Menopausal • Interventional

Huntsman Cancer Institute

Site Contact

Adriana Coletta, PHD, MS, RD

adriana.coletta@hci.utah.edu

801-213-6012

Last Updated: 

05/25/2021

NCT02694029

Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Radiation for Breast Cancer

Female patients treated with radiation for left-sided breast malignancy will undergo alternate fractions of Active Breathing Coordinator (ABC)-assisted and VisionRT-assisted Deep Inspiration Breath-Hold (DIBH).

Completed • Phase NA • Stages 0, I, II, III, IV • Radiation • Post-Menopausal • Interventional

The University of Texas Southwestern Medical Center

Principal Investigator

Asal Rahimi, MD

Last Updated: 

05/25/2021

NCT05662345

ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.

Recruiting • Phase NA • Stages III, IV • HER2 negative • Post-Menopausal • Non-interventional

MCHS Eau Claire

Site Contact

Eyad Al-Hattab

Hattab.Eyad@mayo.edu

Last Updated: 

12/23/2022


Mayo Clinic

Site Contact

Karthik Giridhar

giridhar.karthik@mayo.edu

Last Updated: 

12/23/2022


Mayo Clinic Health System Albert Lea

Site Contact

Mina Hanna, MD

Hanna.Mina@mayo.edu

Last Updated: 

02/24/2023


Mayo Clinic Health System Mankato

Site Contact

Amrit Singh, MBBS

Singh.Amrit@mayo.edu

Last Updated: 

02/24/2023

NCT02946697

A Culturally Sensitive Social Support Intervention

This study is a randomized controlled trial (RCT) to assess the impact of a culturally based social support program (i.e. Joy Luck Academy, JLA) among Chinese American breast cancer survivors.

Recruiting • Phase NA • Stages 0, I, II, III • Surgical • Post-Menopausal • Brain Metastases absent • Interventional

Herald Cancer Association

Site Contact

Alice Loh

626-286-2600

Principal Investigator

Qian Lu, PhD; MD

Last Updated: 

05/25/2021

NCT03091647

Acupressure for Cancer-Related Fatigue

This study develops and pilot tests the efficacy of a home-based, self-administered acupressure intervention in improving cancer-related fatigue (proximal outcome), and physical functioning and other quality of life outcomes (distal outcomes) of Chinese immigrant breast cancer survivors (versus usual care control group).

Active, not recruiting • Phase NA • Stages 0, I, II, III, IV • ER negative • Surgical • Post-Menopausal • Brain Metastases absent • Interventional

Georgetown University

Principal Investigator

Judy Wang, Ph.D.

Last Updated: 

05/25/2021

NCT03783546

Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial

This research study is evaluating acupuncture, a medical therapy in which hair-thin, stainless steel needles are shallowly inserted into specific points to help the body's natural healing process, as a possible treatment to reduce hot flashes.

Active, not recruiting • Phase NA • Stages I, II, III • ER positive • PR positive • Post-Menopausal • Brain Metastases absent • Interventional

Dana Farber Cancer Institute

Principal Investigator

Weidong Lu, PhD, MPH

Last Updated: 

05/25/2021

NCT03505671

Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer

The goal of this study is to obtain preliminary evidence of the effect of 8 acupuncture treatments over 10 weeks in breast and GI cancer patients who are currently receiving or recently completed active neurotoxic chemotherapy and have clinically documented grade 1 or 2 neuropathy.

Completed • Phase NA • Stages I, II, III • Surgical • Post-Menopausal • Interventional

Wake Forest University Health Sciences

Principal Investigator

Nancy Avis

Last Updated: 

05/25/2021

Outcomes4Me

© 2023 Outcomes4Me Inc. All rights reserved.